Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,064.01
(
-0.63%
)
US TECH 100
25,895.20
(
0.09%
)
Dow Jones
49,149.38
(
-0.60%
)
Brent Oil
93.60
(
-1.49%
)
Bitcoin
78,014.64
(
2.21%
)
News Focus
News Focus
Post# of 822358
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

HyGro

Send PM Follow Ignore
Followers 24
Posts 4173
Boards Moderated 0
Alias Born 12/18/2019

HyGro

Re: SkyLimit2022 post# 516333

Friday, 09/23/2022 9:12:38 PM

Friday, September 23, 2022 9:12:38 PM

Post# of 822358
Peer-reviewing clinical trial data is a basic biotech requirement to medical community and investors. Many failed biotechs did it. It is not great value -- it normally has little share price impact. It is a reconfirmation of the clinical data, nothing more.

Doesn't help approvals or any other benefit for shareholders.
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote
Recent NWBO News
More NWBO News